Skip to main content

Drug Interactions between Acid Controller Maximum Strength and raltegravir

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

famotidine raltegravir

Applies to: Acid Controller Maximum Strength (famotidine) and raltegravir

Since raltegravir solubility is increased at higher pH, coadministration with agents that elevate gastric pH may theoretically increase the plasma concentrations of raltegravir. However, concurrent use of proton pump inhibitors or H2-receptor antagonists in clinical trials did not result in meaningful differences in the safety of raltegravir. Based on these data, no dosage adjustment of raltegravir is necessary when used together with proton pump inhibitors or H2-receptor antagonists.

References (1)
  1. (2007) "Product Information. Isentress (raltegravir)." Merck & Co., Inc

Drug and food interactions

Minor

famotidine food

Applies to: Acid Controller Maximum Strength (famotidine)

H2 antagonists may reduce the clearance of nicotine. Cimetidine, 600 mg given twice a day for two days, reduced clearance of an intravenous nicotine dose by 30%. Ranitidine, 300 mg given twice a day for two days, reduced clearance by 10%. The clinical significance of this interaction is not known. Patients should be monitored for increased nicotine effects when using the patches or gum for smoking cessation and dosage adjustments should be made as appropriate.

References (1)
  1. Bendayan R, Sullivan JT, Shaw C, Frecker RC, Sellers EM (1990) "Effect of cimetidine and ranitidine on the hepatic and renal elimination of nicotine in humans." Eur J Clin Pharmacol, 38, p. 165-9

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer